{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.1","upperLimit":"16.8","value":"13.3"},{"groupId":"OG001","lowerLimit":"9.2","upperLimit":"11.3","value":"9.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The primary efficacy endpoint for the study was PFS, defined as time from randomization to the first documentation of PD as determined by blinded independent review or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}